GLP-1 drugs have become some of the most closely watched medicines in diabetes and obesity treatment. These medicines mimic the action of glucagon-like peptide-1 (GLP-1), a hormone involved in blood-sugar regulation, appetite and feelings of fullness.
In 2026, the GLP-1 drug market has expanded beyond traditional injections, with new oral treatments entering the obesity market.
List of GLP-1 Drugs in 2026
| Drug | Active ingredient | Brand | Main use | Form |
|---|---|---|---|---|
| Wegovy | Semaglutide | Wegovy | Obesity/weight management | Injection & tablet |
| Ozempic | Semaglutide | Ozempic | Type 2 diabetes | Injection |
| Rybelsus | Semaglutide | Rybelsus | Type 2 diabetes | Tablet |
| Saxenda | Liraglutide | Saxenda | Obesity/weight management | Injection |
| Victoza | Liraglutide | Victoza | Type 2 diabetes | Injection |
| Trulicity | Dulaglutide | Trulicity | Type 2 diabetes | Injection |
| Byetta | Exenatide | Byetta | Type 2 diabetes | Injection |
| Bydureon BCise | Exenatide | Bydureon BCise | Type 2 diabetes | Injection |
| Adlyxin | Lixisenatide | Adlyxin | Type 2 diabetes | Injection |
| Foundayo | Orforglipron | Foundayo | Obesity/weight management | Oral tablet |
The FDA’s established GLP-1 receptor agonist list includes medicines such as semaglutide, liraglutide, dulaglutide, exenatide and lixisenatide.
New Oral GLP-1 Drug: Foundayo
One of the biggest developments in 2026 is Foundayo (orforglipron) from Eli Lilly.
The FDA approved Foundayo on April 1, 2026, for adults with obesity or overweight with at least one weight-related medical condition, alongside a reduced-calorie diet and increased physical activity. It is taken once daily with or without food, making it different from oral semaglutide formulations that have specific administration requirements.
Foundayo’s approval marks an important shift toward oral GLP-1 weight-loss medicines, potentially offering an alternative to injectable treatments.
Wegovy and Higher-Dose Semaglutide
Wegovy (semaglutide) remains one of the best-known GLP-1 medicines for chronic weight management. In March 2026, the FDA approved Wegovy HD, a higher 7.2 mg dose of injectable semaglutide for certain adults with obesity or overweight and a weight-related condition.
The FDA’s 2026 labeling also lists Wegovy as available in both injection and oral tablet forms, reflecting the rapidly expanding semaglutide market.
GLP-1 vs GIP/GLP-1 Drugs
Not every popular “GLP-1 weight-loss drug” is technically a pure GLP-1 receptor agonist.
Mounjaro and Zepbound contain tirzepatide, which activates both GIP and GLP-1 receptors. They are therefore often called dual GIP/GLP-1 receptor agonists rather than traditional GLP-1-only medicines.
What Is the Best GLP-1 Drug?
There is no single best GLP-1 medicine for everyone. The appropriate treatment depends on the person’s health conditions, treatment goals, medications, contraindications, cost and insurance coverage.
GLP-1 medicines can cause gastrointestinal side effects and have important warnings and contraindications. For example, Foundayo carries a boxed warning concerning thyroid C-cell tumors and should not be used by people with a personal or family history of medullary thyroid carcinoma or MEN 2.
Bottom Line
The 2026 GLP-1 drug landscape now includes established medicines such as Wegovy, Ozempic, Rybelsus, Saxenda, Victoza, Trulicity and exenatide products, alongside the new oral obesity treatment Foundayo (orforglipron).
The arrival of oral GLP-1 medicines could make obesity treatment more convenient, while competition among drugmakers continues to reshape prices, availability and treatment options.
Medical Disclaimer: This article is for educational purposes only and is not medical advice. GLP-1 medicines are prescription drugs and should only be used under the guidance of a qualified healthcare professional. Drug approvals, prices and availability can change.
